Intensity-modulated radiotherapy (IMRT) in the treatment of squamous cell anal canal cancer: acute and early-late toxicity, outcome, and efficacy
| Autor: | Jarek Kobiela, Maria Giulia Zampino, Federica Cattani, Piotr Spychalski, Wanda Petz, Roberto Orecchia, Veronica Dell’Acqua, S. Arculeo, Cristiana Fodor, Paola Simona Ravenda, A. Bazani, Samuele Frassoni, Alessia Surgo, Fatjona Kraja, Vincenzo Bagnardi, Maria Alessia Zerella, Barbara Alicja Jereczek-Fossa, Maria Cristina Leonardi, Marianna Alessandra Gerardi, Rob Glynne-Jones, Maria Saveria Rotundo |
|---|---|
| Přispěvatelé: | Dell'Acqua, V, Surgo, A, Arculeo, S, Zerella, M, Bagnardi, V, Frassoni, S, Zampino, M, Ravenda, P, Rotundo, M, Kraja, F, Kobiela, J, Spychalski, P, Fodor, C, Gerardi, M, Cattani, F, Bazani, A, Petz, W, Glynne-Jones, R, Orecchia, R, Leonardi, M, Jereczek-Fossa, B |
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.medical_treatment Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine Colostomy medicine Anal cancer Chemotherapy Humans IMRT Adverse effect Aged Aged 80 and over Radiotherapy Toxicity business.industry Middle Aged medicine.disease Anus Neoplasms Acute toxicity Radiation therapy Treatment Outcome Response Evaluation Criteria in Solid Tumors 030220 oncology & carcinogenesis Carcinoma Squamous Cell Patient Compliance 030211 gastroenterology & hepatology Female Radiotherapy Intensity-Modulated business Progressive disease |
| Zdroj: | International journal of colorectal disease. 35(4) |
| ISSN: | 1432-1262 |
| Popis: | Purpose: To retrospectively review our experience on 84 patients with squamous cell anal canal cancer (SCAC) within 12 months after combined treatment with intensity-modulated RT (IMRT), in terms of acute and early-late toxicity, overall treatment time and interruptions, colostomy-free survival (CFS), and tumor response. Methods: Acute gastrointestinal (GI), genitourinary (GU), and cutaneous (CU) toxicities were assessed according to Common Toxicity Criteria for Adverse Events (CTCAE) version 4.03. Early-late toxicity was scored using the Radiation Therapy Oncology Group (RTOG) late radiation morbidity scoring system. Tumor response was evaluated with response evaluation criteria in solid tumors (RECIST) v1.1. Results: Acute toxicity for 84 subjects (100%): severe (≥ G3) GI and skin toxicity was observed in 4 (5%) and 19 patients (23%), respectively. Early-late toxicity for 73 subjects (87%): severe (≥ G3) GI and vulvo-vaginal toxicity was observed in 2 (3%) and 2 (3%) patients, respectively. No acute or early-late severe GU toxicity was reported. A treatment interruption occurred in 65 patients (77%). CFS was 96% (95% CI 89–99) at 6 months and 92% (95% CI 83–96) at 12 months. At 6 months complete response (CR), partial response (PR) and progressive disease (PD) was observed in 70 (83%), 3 (4%), and 7 patients (8%), respectively. At 12 months, CR was observed in 60 patients (81%); eleven patients (15%) experienced PD. Conclusion: Our study showed an excellent clinical result and very low acute toxicity rates, confirming the IMRT as standard of care for curative treatment of anal cancer patients. The current trial was registered with the number IEO N87/11 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink